English | Japanese (日本語)
Evaluate Pharma Heading
Evaluate Pharma
 
Login Now

EvaluatePharma® – helping you to find value in the pharmaceuticals and biotechnology sector.

EvaluatePharma® provides comprehensive coverage of more than 900 companies and nearly 15,000 products from early stage R&D through to Marketed and beyond, tracking the past and future performance of the pharma and biotech business sectors.

Historic sales (since 1986), consensus forecasts to 2014, peak sales and detailed company financials, including earnings estimates to 2014, are delivered via an exceptionally user-friendly web interface.

Consensus forecasts are compiled from the reports of leading securities analysts, and include sales forecasts to 2014, forecast range (min and max; median), and analyst forecast dates, updated on a monthly basis.

Company-reported quarterly sales are uploaded as they become available, while news items are classified and added daily.

It’s easy to customize any report to meet your market analysis needs.

  • Perform instant company merger analysis
  • Benchmark against industry peer groups and their products in seconds
  • Identify key industry growth drivers at the glance of a chart
  • Compare your forecasts against the industry’s consensus forecasts effortlessly
  • Create comprehensive macro level Company Rankings or Therapy Rankings Reports by historic sales or forecasts out to 2014
  • Gain insights into all sales at risk from patent expiries
  • Plus volumes of other industry analysis

EvaluatePharma® helps you find the answers you need!

Click here to view Sample Company Reports from EvaluatePharma.


 Login     Events and conferences  

 


World Preview 2012 WORLD PREVIEW 2012 World Preview 2012
Global analysis & insights from EvaluatePharma

REQUEST YOUR FREE COPY



EvaluatePharma Alpha

Cutting-edge analysis and intelligence service for the pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

Find out more


RECENT ANALYSESMore
High hopes for almorexant?
July 14, 2008 - Actelion was probably hoping for a slightly more effusive reaction to its heavily trailed SFr3.3bn ($3.2bn) deal with GlaxoSmithKline for insomnia drug almorexant announced today, rather than the meagre 4% advance its share price notched up.
 
PRESS ROOMMore
Forecasts extended to 2014
July 30th 2008: EvaluatePharma has extended consensus forecasts to 2014 on all product forecasts, therapy area sales, company portfolio analysis and financial statements.
 
Email this page to a colleague
Home | About Us | Sample Reports | Conferences | Contact Us | FAQs | LegalEPHMRA LogoPBIRG Logo